## Scott K Winiecki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9532874/publications.pdf

Version: 2024-02-01

1307594 1372567 11 235 7 10 citations g-index h-index papers 11 11 11 411 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood, 2016, 127, 200-207.	1.4	52
2	Intravenous immune globulin and thromboembolic adverse events: A systematic review and metaâ€analysis of RCTs. American Journal of Hematology, 2016, 91, 594-605.	4.1	47
3	Adverse events following measles, mumps, and rubella vaccine in adults reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013. Clinical Infectious Diseases, 2015, 60, e58-65.	5 <b>.</b> 8	40
4	Motor palsies of cranial nerves (excluding VII) after vaccination. Human Vaccines and Immunotherapeutics, 2014, 10, 301-305.	3.3	34
5	Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013–2015. Vaccine, 2015, 33, 6684-6688.	3.8	19
6	Complementary use of passive surveillance and Miniâ€Sentinel to better characterize hemolysis after immune globulin. Transfusion, 2015, 55, S28-35.	1.6	17
7	Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems. Drug Safety, 2017, 40, 571-582.	3.2	17
8	The culture of research communication in neonatal intensive care units: key stakeholder perspectives. Journal of Perinatology, 2021, , .	2.0	5
9	Pediatric registries at the Food and Drug Administration: design aspects that increase their likelihood of success. Pharmacoepidemiology and Drug Safety, 2016, 25, 602-605.	1.9	3
10	Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012). Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	1
11	FDA collaboration to improve safe use of fluoroquinolone antibiotics: an ex post facto matched control study of targeted short-form messaging and online education served to high prescribers. Pharmacy Practice, 2020, 18, 1773.	1.5	O